Meyahealth
HomeGeneticsConditionHypochromic microcytic anemia with iron overload
Back to Condition
Hypochromic microcytic anemia with iron overload
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Hypochromic microcytic anemia with iron overload

This rare genetic condition impairs iron transport, leading to a shortage of red blood cells and the accumulation of iron in the liver.

Overview

Hypochromic microcytic anemia with iron overload is a condition that impairs the normal transport of iron in cells. Iron is an essential component of hemoglobin, the substance red blood cells use to carry oxygen throughout the body. In this condition, red blood cells cannot access iron, leading to a decrease in red blood cell production (anemia) present at birth. The red blood cells that are produced are abnormally small (microcytic) and pale (hypochromic).

Symptoms

Symptoms of the anemia include:

  • Pale skin (pallor)
  • Tiredness (fatigue)
  • Slow growth

Because the iron is not used by red blood cells, it accumulates in the liver, which can impair liver function. These liver problems typically become apparent in adolescence or early adulthood.

Causes

The condition is caused by mutations in the SLC11A2 gene, which provides instructions for making the protein divalent metal transporter 1 (DMT1). This protein transports iron within cells. In the small intestine, DMT1 helps absorb iron from food; in other cells, such as immature red blood cells (erythroblasts), it transports iron from specialized compartments called endosomes into the cytoplasm for use.

Mutations in SLC11A2 reduce the function or availability of DMT1. In erythroblasts, this prevents iron from attaching to hemoglobin, impairing red blood cell development. In the intestine, the body attempts to compensate for the perceived iron shortage by increasing iron absorption, but because the red blood cells cannot utilize this iron, it accumulates in the liver.

Inheritance

This condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. Parents of an affected individual each carry one copy of the mutated gene but typically do not show signs or symptoms of the condition.

Other Names

  • Microcytic anemia and hepatic iron overload
  • Microcytic anemia with liver iron overload

Frequently Asked Questions

Iron overload is typically assessed with a combination of blood tests and imaging. Serum ferritin and transferrin saturation give a first indication of iron stores, but they can be influenced by inflammation. Magnetic resonance imaging (MRI) using T2* or R2* sequences is the gold standard for quantifying hepatic iron concentration noninvasively. In selected cases, a liver biopsy may be performed to confirm the diagnosis and evaluate for fibrosis or cirrhosis. Regular monitoring (every 6–12 months) helps guide treatment adjustments. What dietary modifications can help manage iron absorption without worsening anemia?::Because the red blood cells cannot utilize iron, excess dietary iron can accumulate. Patients are advised to limit iron‑rich foods such as red meat, liver, and fortified cereals. Avoid taking iron supplements unless prescribed. Pairing meals with vitamin C (which increases absorption) should be avoided or limited. Calcium‑rich foods or supplements can inhibit iron absorption and may be recommended. A dietitian can tailor a plan that balances adequate nutrition with reduced iron load. Can iron chelation therapy be used, and what are the risks and benefits in this condition?::Yes, chelators such as deferoxamine, deferasirox, or deferiprone are used to remove excess hepatic iron. Benefits include preventing liver damage, reducing cardiac complications, and improving overall iron balance. Risks involve injection site reactions (deferoxamine), gastrointestinal upset, renal or hepatic toxicity (deferasirox), and bone marrow suppression (deferiprone). Regular monitoring of blood counts, liver and kidney function, and serum ferritin is essential to adjust dosing and minimize side effects. How does the condition affect growth and development in children, and what interventions can support normal growth?::Anemia and liver dysfunction can impair growth velocity and puberty timing. Interventions include regular blood transfusions to maintain hemoglobin levels, careful iron chelation to prevent organ damage, and nutritional support to ensure adequate calories and protein. Growth hormone therapy has been explored in some cases, but its use must be weighed against potential risks. Early involvement of a multidisciplinary team—hematology, gastroenterology, nutrition, and endocrinology—helps optimize growth outcomes.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ